| Species |
Human |
| Protein Construction |
HAI-1 (Gly36-Val433)
Accession # O43278-2 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its ability to inhibit trypsin cleavage of a fluorogenic peptide substrate, McaArgProLysProValGluNVALTrpArgLys(DNP)NH2. The IC50 is < 1 nM. Test result meets the standard. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
45.50 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 50-70 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
SPINT1, also known as HAI-1, is a Kunitz-type serine protease inhibitor that inhibits multiple proteases including hepatocyte growth factor (HGF) activator and matriptase. SPINT1 has been shown to modulate HGF/MET activation in certain cancer types. |
| Synonyms |
HAI 1; SPINT1; HAI1; HAI-1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
